Less than four weeks after being accused by a former employee of sex discrimination, a fast-growing local startup has settled the lawsuit.
Iggbo announced Wednesday it has come to terms on a resolution of a case filed last month against the Henrico-based company and two of its top executives by its former VP of operations, Janis Rosenberg.
The settlement amount was not disclosed, as is typical in such cases. Rosenberg’s suit did not specify the amount of damages sought.
The resolution was reached through a mediation session Tuesday.
The initial suit was filed Oct. 12 in Richmond Federal Court, claiming sex discrimination, retaliation and breach of contract against Iggbo. Rosenberg concurrently sued CEO Nuno Valentine and chief medical officer Shaival Kapadia for defamation.
The sex discrimination allegation stemmed from Rosenberg’s claim that she never received a promised equity stake in the firm after allegedly enduring sexual harassment from her former boss, the late Iggbo co-founder Mark Van Roekel.
A joint statement sent through Iggbo’s lawyer Tom Roberts of Thomas H. Roberts & Associates said Iggbo, Valentine, Kapadia and Rosenberg “have resolved all differences and disputes to their mutual satisfaction.”
The joint statement says Iggbo, Valentine and Kapadia acted “immediately and appropriately to investigate Janis Rosenberg’s claims once the claims were disclosed,” referring to a complaint Rosenberg filed to the company of alleged sexual harassment by Van Roekel, who court filings say committed suicide shortly after the internal complaint.
“Valentine and Kapadia understand Rosenberg’s concerns for a respectful workplace and her own wellbeing,” the joint statement reads. “Rosenberg understands that no actions by Valentine and Kapadia were undertaken with ill will or malice towards Rosenberg and that all their actions were taken in the best interest of the company and its employees.”
Iggbo said earlier this week it decided to take the case to mediation rather than “wasting countless hours in litigation,” instead wanting to get back to its Uber-like business model to simplify the blood-drawing process.